Brief: Oncolytics Biotech Qtrly basic and diluted loss per common share $0.03
Nov 3 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* Qtrly basic and diluted loss per common share $0.03
* Oncolytics Biotech Inc. announces 2016 third quarter
results
Source text for Eikon: ID:nCNWD5g0La
Further company coverage: ONC.TO
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer